GT201000099A - Productos quimioterapéuticos cristalinos - Google Patents

Productos quimioterapéuticos cristalinos

Info

Publication number
GT201000099A
GT201000099A GT201000099A GT201000099A GT201000099A GT 201000099 A GT201000099 A GT 201000099A GT 201000099 A GT201000099 A GT 201000099A GT 201000099 A GT201000099 A GT 201000099A GT 201000099 A GT201000099 A GT 201000099A
Authority
GT
Guatemala
Prior art keywords
crystal
chemotherapeutic products
chemotherapeutic
products
methylpenyl
Prior art date
Application number
GT201000099A
Other languages
English (en)
Inventor
Thomas B Borchardt
Alexander Chu-Kung
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Publication of GT201000099A publication Critical patent/GT201000099A/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D231/00Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/54Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
    • C07D231/56Benzopyrazoles; Hydrogenated benzopyrazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

LA PRESENTE INVENCIÓN SE REFIERE A LA FORMA CRISTALINA 2 DE N-[4-(3-AMINO-1H-INDAZOL-4-IL) FENIL]-N´- (2-FLUORO -5-METILFENIL)UREA(ABT-869) QUE PERTENECE A UNA FAMILIA DE PROTEÍNA TIROSINA QUINASA (PTK) QUE CATALIZAN LA FOSFORILACIÓN DE RESIDUOS ESPECÍFICOS DE TIROSINA EN PROTEÍNAS POR LO QUE SON DE UTILIDAD EN TRASTORNOS O ENFERMEDADES PROLIFERATIVAS MALIGNAS RESULTANTES DE LA ACTIVACIÓN INAPROPIADA DEL SISTEMA INMUNE.
GT201000099A 2007-10-19 2010-04-16 Productos quimioterapéuticos cristalinos GT201000099A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US98126507P 2007-10-19 2007-10-19

Publications (1)

Publication Number Publication Date
GT201000099A true GT201000099A (es) 2012-03-26

Family

ID=40174735

Family Applications (1)

Application Number Title Priority Date Filing Date
GT201000099A GT201000099A (es) 2007-10-19 2010-04-16 Productos quimioterapéuticos cristalinos

Country Status (19)

Country Link
US (1) US7772404B2 (es)
EP (1) EP2195299A1 (es)
JP (1) JP2011500708A (es)
KR (1) KR20100084665A (es)
CN (1) CN101827825B (es)
AU (1) AU2008312534A1 (es)
BR (1) BRPI0818337A2 (es)
CA (1) CA2699356A1 (es)
CO (1) CO6270221A2 (es)
CR (1) CR11444A (es)
DO (1) DOP2010000111A (es)
EC (1) ECSP10010175A (es)
GT (1) GT201000099A (es)
MX (1) MX2010004287A (es)
PA (1) PA8800401A1 (es)
RU (1) RU2010119920A (es)
UA (1) UA99490C2 (es)
WO (1) WO2009052231A1 (es)
ZA (1) ZA201002094B (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20140031769A1 (en) 2010-11-19 2014-01-30 Forsight Vision4, Inc. Therapeutic agent formulations for implanted devices
EP2739252A4 (en) 2011-08-05 2015-08-12 Forsight Vision4 Inc SMALL MOLECULE ADMINISTRATION USING AN IMPLANTABLE THERAPEUTIC DEVICE
EP2968113B8 (en) 2013-03-14 2020-10-28 Forsight Vision4, Inc. Systems for sustained intraocular delivery of low solubility compounds from a port delivery system implant
MY182793A (en) 2014-08-08 2021-02-05 Forsight Vision4 Inc Stable and soluble formulations of receptor tyrosine kinase inhibitors, and methods of preparation thereof

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7297709B2 (en) * 2003-05-22 2007-11-20 Abbott Laboratories Indazole, benzisoxazole, and benzisothiazole kinase inhibitors
PL1638941T3 (pl) * 2003-05-22 2010-11-30 Abbvie Bahamas Ltd Indazolowe, benzizoksazolowe i benzizotiazolowe inhibitory kinaz
US20100105031A1 (en) * 2005-08-01 2010-04-29 Esai R & D Management Co., Ltd. Method for prediction of the efficacy of vascularization inhibitor
WO2007015578A1 (ja) * 2005-08-02 2007-02-08 Eisai R & D Management Co., Ltd. 血管新生阻害物質の効果を検定する方法
WO2007076358A1 (en) * 2005-12-23 2007-07-05 Alcon, Inc. PHARMACEUTICAL FORMULATION FOR DELIVERY OF RECEPTOR TYROSINE KINASE INHIBITING (RTKi) COMPOUNDS TO THE EYE
CA2667720A1 (en) * 2006-11-09 2008-05-15 Abbott Gmbh & Co. Kg. Pharmaceutical dosage form for oral administration of tyrosine kinase inhibitor

Also Published As

Publication number Publication date
CR11444A (es) 2010-10-05
US20090124816A1 (en) 2009-05-14
RU2010119920A (ru) 2011-11-27
MX2010004287A (es) 2010-04-30
WO2009052231A1 (en) 2009-04-23
CN101827825A (zh) 2010-09-08
EP2195299A1 (en) 2010-06-16
CO6270221A2 (es) 2011-04-20
AU2008312534A1 (en) 2009-04-23
ECSP10010175A (es) 2010-06-29
CN101827825B (zh) 2012-11-21
DOP2010000111A (es) 2010-07-15
JP2011500708A (ja) 2011-01-06
PA8800401A1 (es) 2009-05-15
BRPI0818337A2 (pt) 2017-05-23
KR20100084665A (ko) 2010-07-27
UA99490C2 (en) 2012-08-27
US7772404B2 (en) 2010-08-10
CA2699356A1 (en) 2009-04-23
ZA201002094B (en) 2011-11-30

Similar Documents

Publication Publication Date Title
CY1121572T1 (el) Σκευασμα δισκιου του ν-[2,4-δις(1,1-διμεθυλαιθυλ)-5-υδροξυφαινυλ]-1,4-διυδρο-4-οξοκινολινο-3-καρβοξαμιδιου για χρηση στη θεραπεια κυστικης ινωσης
NO20085243L (no) Farmasoytisk sammensetning til behandling av virusinfeksjoner og/eller tumorsykdommer gjennom inhibering av proteinfolding og Proteinnedbryting
CY1109084T1 (el) Προϊον ζαχαροπλαστικης με χαμηλα λιπαρα
BR112014027244A2 (pt) derivados de benzamida para inibição da atividade de abl1, abl2 e bcr-abl1
EA201691242A1 (ru) Фармацевтические композиции, содержащие azd9291
BR112014028841A2 (pt) processo para preparação de n-[5-(3,5-difluoro-benzil)-1h-indazol-3-il]-4-(4-metil-piperazin-l-il)-2-(tetra-hidro-piran-4-ilamino)-benzamida
BR122021002201A8 (pt) Composto, composição, uso de um composto, e, método de tratamento de um distúrbio, condição ou doença
EA201270225A1 (ru) СОЕДИНЕНИЯ ДЛЯ УМЕНЬШЕНИЯ ПРОДУКЦИИ β-АМИЛОИДА
CL2007002949A1 (es) Forma cristalina del compuesto 2-cloro-5-(3,6-dihidro-3-metil-2,6-dioxo-4-(trifluorometil)-1-(2h)-pirimidinil)-4-fluoro-n-((metil(1-metiletil)amino)sulfonil)benzamida; proceso para la preparacion de dicha forma cristalina; composicion fitoprotectora;
EA201270361A1 (ru) Птеридины и их применение в качестве агрохимикатов
BR112018073951A2 (pt) forma cristalina inovadora de n-[5-(3,5-difluoro-benzil)-1h-indazol-3-il]-4-(4-metil-piperazin-1-il)-2-(tetra-hidro-piran-4-ilamino)-benzamida
GT201000099A (es) Productos quimioterapéuticos cristalinos
AR065278A1 (es) Sales de derivado de benzotiazol
GT201000101A (es) Productos quimioterapéuticos cristalinos
EA201390351A1 (ru) Спрей для носа
RS54639B1 (en) PCSK9 VACCINE
MA32717B1 (fr) Sels de n-[6-cis- (2.6-dimethylmorpholin-4-yl)pyridin-3-yl)-2-methyl-4'- (trifluoromethoxy)- [1.1'-biphenyl]-3-carboxamide
ITCR20050007A1 (it) Fondello di supporto per prodotti cosmetici
IL189286A0 (en) Novel cysteine protease inhibitors and their therapeutic applications
ATE472316T1 (de) Haarbehandlungszusammensetzungen
GT200600141A (es) Utilización de agomelatina para la obtención de medicamentos destinados al tratamiento de trastornos bipolares
DOP2010000112A (es) Productos quimioterapeuticos cristalinos
EA200702318A1 (ru) Применение агомелатина для получения лекарственных средств, предназначенных для лечения синдрома смита-магениса
GT201000093A (es) Productos quimioterapéuticos cristalinos
MX2008007195A (es) Inhibidores de proteasas de cisteina, composiciones farmaceuticas de las mismas y sus aplicaciones terapeuticas.